Skip to main content

Table 3 Rates of irAEs in the Italian Early Access Program of nivolumab in mRCC

From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

irAEs

G1

N (%)

G2

N (%)

G3

N (%)

G4

N (%)

Any grade

N (%)

Cutaneous

16 (4)

12 (3)

2 (1)

0

30 (8)

Endocrine

10 (3)

5 (1)

1 (< 1)

1 (< 1)

17 (4)

Hepatic

5 (1)

2 (1)

0

0

7 (2)

Gastro-intestinal

8 (2)

7 (2)

4 (1)

0

19 (5)

Pulmonary

1 (< 1)

1 (< 1)

2 (1)

0

4 (1)

  1. Abbreviations: N number, irAEs immune-related adverse events